Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00130819
Other study ID # H97HA03794
Secondary ID HRSA-04-078
Status Completed
Phase Phase 2
First received August 15, 2005
Last updated April 14, 2015
Start date November 2005
Est. completion date April 2009

Study information

Verified date April 2009
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the effectiveness of two approaches to treating HIV-infected patients who are addicted to opioid drugs (e.g., heroin) in an inner-city HIV clinic. The two approaches are:

- Case management and referral - participants are managed by a case manager and referred to a specialized drug treatment center where they receive counseling and medications for opioid-dependence (e.g., methadone or buprenorphine); or

- Clinic-based treatment - participants receive counseling and treatment with buprenorphine at the HIV clinic.


Description:

We, the investigators at Johns Hopkins University, propose to enroll and randomize 120 opioid-dependent, HIV-infected participants, who receive care in the Johns Hopkins HIV Clinic to either:

- clinic-based care with buprenorphine (clinic-based BPN/NX arm); or

- case management and referral to an opioid treatment program for opioid agonist-based therapy (case management and referral arm).

The study interventions and follow-up will last 12 months. Participants will be enrolled over a 3-year period. Participants who are assigned to the clinic-based BPN/NX arm will receive BPN/NX (Suboxone®), individual counseling from a nurse interventionist, and group therapy sessions. Participants who are assigned to the case management and referral arm will be enrolled in an established case management and adherence program in the Johns Hopkins HIV Clinic (Project LINK). LINK provides intensive case management, education, and support by a team that includes a social worker, a nurse, a pharmacist educator, and peer advocates. In addition to providing counseling and linkage to needed services, LINK will expedite intake at licensed opioid treatment programs that provide agonist-based therapy for opioid dependence. The clinic-based BPN intervention is a new strategy that was developed in a pilot project over the past 6 months. The case-management and referral arm represents standard-of-care in our clinic, which has been enhanced and codified for this trial. Study outcome visits will be performed at baseline, 1 month, 3 months, 6 months, 9 months, and 12 months.

Comparisons:

- Retention to substance abuse treatment;

- Urine drug screens;

- Adherence to HIV primary care provider visits;

- Use of and adherence to highly active antiretroviral therapy (HAART);

- HIV RNA levels and CD4 cell counts;

- HIV transmission risk behaviors (e.g., injection, sharing of drug paraphernalia, sexual behaviors);

- Costs and resource utilization.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date April 2009
Est. primary completion date April 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- HIV-infected and receiving continuity care in the Johns Hopkins HIV Clinic

- 18 years of age or older

- Meets DSM-IV criteria for opioid dependence

- Seeks agonist-based treatment for opioid dependence

- Willing and able to provide written informed consent

- Willing to be contacted by mail and telephone for study follow-up visit reminders

- Willing to authorize release of information for substance abuse treatment to the study for a period of 12 months

- If female, negative urine pregnancy test and willingness to practice birth control while on study if sexually active (barrier method or progesterone-containing contraception product)

- Verbal approval from participant's primary HIV clinician

Exclusion Criteria:

- Currently receiving methadone, naloxone, buprenorphine, or levomethadyl acetate (LAAM) as part of a licensed opioid treatment program

- History of allergic reaction to buprenorphine or naloxone

- Active medical need for opioid-based pain control

- Active benzodiazepine abuse or dependence

- Active alcohol dependence

- Alanine aminotransferase level that is more than 5 times the upper limit of normal

- Other condition that, in the opinion of the principal investigator, makes participation in the study unsafe or follow-up highly unlikely

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Behavioral:
Clinic-based substance abuse treatment with buprenorphine
Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
Case management and referred substance abuse treatment
Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence

Locations

Country Name City State
United States Johns Hopkins HIV Clinic Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins University The New York Academy of Medicine

Country where clinical trial is conducted

United States, 

References & Publications (1)

Lucas GM, Chaudhry A, Hsu J, Woodson T, Lau B, Olsen Y, Keruly JC, Fiellin DA, Finkelstein R, Barditch-Crovo P, Cook K, Moore RD. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Retention to substance abuse treatment 12 months No
Secondary Visit attendance with primary medical provider 12 months No
Secondary Urine drug screen positivity for opioids and other drugs 12 months No
Secondary Use of and adherence to highly active antiretroviral therapy (HAART) 12 months No
Secondary HIV RNA changes 12 months No
Secondary CD4 cell count changes 12 months No
Secondary Self-reported HIV transmission risk behaviors 12 months No
Secondary Costs and resource utilization 12 months No
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2